Selective Nav1.7 channel blocker (IC50 = 370 nM). Exhibits >85-fold selectivity for Nav1.7 over Nav1.5 and hERG channels. Reduces nociceptive behavior in rat models of pain.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 434.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.3 mL||11.51 mL||23.02 mL|
|5 mM||0.46 mL||2.3 mL||4.6 mL|
|10 mM||0.23 mL||1.15 mL||2.3 mL|
|50 mM||0.05 mL||0.23 mL||0.46 mL|
References are publications that support the biological activity of the product.
Macsari et al (2012) 3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models. J.Med.Chem. 55 6866 PMID: 22770500
If you know of a relevant reference for NAV 26, please let us know.
View Related Products by Product Action
Keywords: NAV 26, NAV 26 supplier, NAV26, selective, NAv1.7, ion, channels, blockers, Voltage-gated, Sodium, Channels, 4691, Tocris Bioscience
Citations for NAV 26
Citations are publications that use Tocris products.
Currently there are no citations for NAV 26. Do you know of a great paper that uses NAV 26 from Tocris? Please let us know.
Reviews for NAV 26
There are currently no reviews for this product. Be the first to review NAV 26 and earn rewards!
Have you used NAV 26?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.